Reused palm oil from frying pork or potato induced expression of cytochrome P450s and the SLCO1B1 transporter in HepG2 cells

The effect of krill oil on longevity and locomotion: a pilot study

Krill oil as a dietary supplement is popular with consumers. Several experimental and clinical trials have suggested that krill oil is beneficial for longevity and locomotion, but the underlying mechanisms for this have remained largely elusive. In this study, we investigated alleviation of impairment of Caenorhabditis elegans by polar compounds from frying oil with the use of krill oil. Observations of life span and locomotion demonstrated that the intake of krill oil increased median survival by 17.86%, head thrashes by 27.79% and body bends by 20.78% for impaired C. elegans. Metabolomic analysis revealed that krill oil could significantly restore the negative alterations caused by polar compounds, including upregulation of serine, tyrosine, palmitic acid and stearic acid, and downregulation of maltose 6'-phosphate, UDP-glucose, glutamic acid, phosphoserine and 25-hydroxyvitamin D3. Additionally, intake of krill oil also changed some metabolites that were irrelevant to impairment by polar compounds, but were beneficial for health for C. elegans. Metabolomics investigations indicated that krill oil ameliorates energy metabolism and alleviates oxidative stress and excitotoxicity caused by polar compounds on C. elegans. The data obtained in this study will facilitate future functional studies of krill oil.

Effect of fenofibrate on proliferation of SMMC-7721 cells via regulating cell cycle

Liver cancer is a malignant cancer with great harmfulness. Fenofibrate is a peroxisome proliferation activated receptor (PPARα) agonist widely used in the treatment of dyslipidemia. Previous studies have shown that fenofibrate may promote cell proliferation, but the underlying mechanism has not been fully characterized. The aim of this study was to investigate the role of PPARα agonist fenofibrate in cell proliferation of SMMC-7721 cells compared with that of THLE-2 cells. SMMC-7721 and THLE-2 cells were treated with different concentrations of fenofibrate. Cell proliferation was analyzed by MTT, using flow cytometry for cell cycle analysis, and CyclinD1, Cyclin-dependent kinases2 (CDK2) and Proliferating Cell Nuclear Antigen (PCNA) were analyzed by Western blotting. RT-qPCR method was used to assess CDK2, CyclinD1 and PCNA mRNA levels. The results showed that 10^-9-10^-4 mol/L fenofibrate could induce cell growth and 10^-4, 10^-5, 10^-6 mol/L fenofibrate could reduce the number of G0/G1 phase cells and increased in the number of cells in S and G2/M phase of cell cycle in SMMC-7721 cells. Furthermore, fenofibrate could significantly increase the expression of cell cycle related protein (CyclinD1, CDK2)and cell proliferation related proteins (PCNA). The use of PPARα inhibitor MT886 inhibited cell cycle progression and promote tumor cell apoptosis. But fenofibrate had no obvious effect on THLE-2 cells. These results revealed the effect of fenofibrate on the cell cycle of liver cancer cells, and provided a reasonable explanation for studying how fenofibrate promotes cell proliferation.